Acro Biomedical CO., LTD. (ACBM) — SEC Filings

Overview

Acro Biomedical CO., LTD. (ACBM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the three and nine months ended September 30, 2025, continuing a trend of no sales since December 31, 2022. The company's net loss significantly widened to $(117,809) for the three months ended September 30, 2025, compared to $(10,229) in the

Sentiment Summary

Across 9 filings, the sentiment breakdown is: 6 bearish, 2 neutral, 1 mixed. The dominant filing sentiment for Acro Biomedical CO., LTD. is bearish.

Filing Type Overview

Acro Biomedical CO., LTD. (ACBM) has filed 5 10-Q, 2 8-K, 2 10-K with the SEC between Jul 2025 to Nov 2025.

Recent Filings (9)

• ACBM's Losses Skyrocket Amid Zero Revenue, Going Concern Doubts Mount — 10-Q · Nov 10, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the three and nine months ended September 30, 2025, continuing a trend of no sales since December 31, 2
• Acro Biomedical Files 8-K on Officer and Director Changes — 8-K · Aug 14, 2025 Risk: medium
  On August 14, 2025, ACRO BIOMEDICAL CO., LTD. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also disclosed
• ACBM Reports Zero Revenue, Continued Losses in Q2 2025 — 10-Q · Aug 5, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the six months ended June 30, 2025, consistent with the prior year period. The company recorded a net l
• ACBM Remains Pre-Revenue, Eyes Capital for Biomedical Future — 10-K · Jul 24, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the fiscal year ended December 31, 2024, consistent with the prior year, indicating a pre-revenue or no
• ACBM Boosts Share Count Amidst Zero Revenue, Q2 2024 — 10-Q · Jul 23, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the six months ended June 30, 2024, consistent with the prior year period. The company's net loss for t
• ACBM Posts No Revenue, Eyes Hong Kong for Future Growth — 10-Q · Jul 22, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) filed its 10-Q for the quarter ended March 31, 2024, indicating no revenue or net income for the period, consistent with its de
• ACBM Revenue Skyrockets 300,000% on Concentrated Customer Base — 10-K · Jul 18, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) reported a significant increase in revenue from contracts with customers, reaching $60,042,000 in 2023, up from $20,000 in 2022
• ACBM Reports Zero Revenue, Issues 60M Shares for Services — 10-Q · Jul 11, 2025 Risk: high
  ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the nine months ended September 30, 2023, consistent with the prior year, indicating a lack of operatio
• Acro Biomedical Changes Certifying Accountant — 8-K · Jul 2, 2025 Risk: low
  On July 1, 2025, ACRO BIOMEDICAL CO., LTD. filed an 8-K report indicating a change in its certifying accountant. The company previously engaged WithumSmith+Brow

Risk Profile

Risk Assessment: Of ACBM's 9 recent filings, 7 were flagged as high-risk, 1 as medium-risk, and 1 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.

Financial Highlights

Key financial metrics from Acro Biomedical CO., LTD.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $0
• Net Income: $(117,809)
• EPS: $0.00
• Debt-to-Equity: N/A
• Cash Position: $4,323
• Operating Margin: N/A
• Total Assets: $4,323
• Total Debt: $436,942

Key Executives

• minority stockholder
• chief executive officer

Industry Context

ACRO BIOMEDICAL CO., LTD. operates in the nutritional products sector, specifically focusing on cordyceps-related items. This market is influenced by traditional medicine practices, particularly in Asia. The industry can be subject to fluctuating consumer demand, regulatory scrutiny regarding health claims, and competition from both established brands and emerging players offering wellness products.

Top Tags

Biomedical (7) · SEC Filing (4) · High Risk (3) · Speculative Investment (3) · Zero Revenue (2) · Development Stage (2) · Penny Stock (2) · No Revenue (2) · Customer Concentration (2) · Cordyceps (1)

Key Numbers

• Revenue: $0 — for the three and nine months ended September 30, 2025, and since December 31, 2022
• Net Loss: $(117,809) — for the three months ended September 30, 2025, a 1051% increase from $(10,229) in 2024
• Selling, General and Administrative Expenses: $115,099 — for the three months ended September 30, 2025, compared to $9,106 in 2024
• Cash: $4,323 — as of September 30, 2025, up from $476 at December 31, 2024
• Due to related parties: $300,360 — as of September 30, 2025, up from $125,588 at December 31, 2024
• Accumulated Deficit: $(32,801,467) — as of September 30, 2025
• Advances from related parties: $174,772 — for the nine months ended September 30, 2025
• Shares of common stock outstanding: 60,042,000 — as of November 10, 2025
• Imputed interest rate: 4% — on related party advances
• Total Assets: $0 — Zero assets as of June 30, 2025, highlighting a lack of operational infrastructure.
• Net Loss (Q2 2025): $1,000 — Consistent net loss for the quarter, showing ongoing operational expenses without income.
• Net Loss (YTD 2025): $2,000 — Year-to-date net loss, reflecting continued financial drain without revenue generation.
• Common Shares Outstanding: 60,042,000 — Total shares outstanding as of December 31, 2024, indicating potential for dilution.
• Authorized Common Shares: 100,000,000 — Maximum shares the company can issue, allowing for significant future capital raises.
• Par Value per Share: $0.001 — Nominal value of each common stock share.

Frequently Asked Questions